Cover Image

Da Volterra - 產品平台分析

Da Volterra - Product Pipeline Review - 2014

出版商 Global Markets Direct 商品編碼 311246
出版日期 內容資訊 英文 21 Pages
Back to Top
Da Volterra - 產品平台分析 Da Volterra - Product Pipeline Review - 2014
出版日期: 2014年08月25日 內容資訊: 英文 21 Pages



Da Volterra是開發並提供攸關生死的細菌感染及抗生物無效的醫療保健解決方案之生物科技企業。該公司在細菌性感染疾病,抗生素抗藥性,院內感染治療領域開發著感染性疾病的治療藥及預防藥、抗生素抗藥性抑制、藥物輸送、微生物、抗菌抗性、抗生素抗性臨床及前臨床開發。

本報告提供Da Volterra 的治療藥開發平台現狀及各開發階段比較分析,為您彙整藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Da Volterra的基本資料

Da Volterra概要

  • 主要資訊
  • 企業資料

Da Volterra:R&D概要

  • 主要的治療範圍

Da Volterra:開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式

Da Volterra:開發中產品概況

  • 初期階段產品開發中產品
    • 前臨床階段的產品/聯合治療模式

Da Volterra:藥物簡介

  • DAV-121
  • DAV-148
  • DAV-210

Da Volterra:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Da Volterra:總公司和子公司的所在地



Product Code: GMDHC06093CDB


Global Markets Direct's, 'Da Volterra - Product Pipeline Review - 2014', provides an overview of the Da Volterra's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Da Volterra's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


  • The report provides brief overview of Da Volterra including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Da Volterra's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Da Volterra's pipeline products

Reasons to buy

  • Evaluate Da Volterra's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Da Volterra in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Da Volterra's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Da Volterra and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Da Volterra
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Da Volterra and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Da Volterra Snapshot
    • Da Volterra Overview
    • Key Information
    • Key Facts
  • Da Volterra - Research and Development Overview
    • Key Therapeutic Areas
  • Da Volterra - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Da Volterra - Pipeline Products Glance
    • Da Volterra - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Da Volterra - Drug Profiles
    • DAV-121
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DAV-148
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DAV-210
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Da Volterra - Pipeline Analysis
    • Da Volterra - Pipeline Products by Target
    • Da Volterra - Pipeline Products by Route of Administration
    • Da Volterra - Pipeline Products by Molecule Type
    • Da Volterra - Pipeline Products by Mechanism of Action
  • Da Volterra - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Da Volterra, Key Information
  • Da Volterra, Key Facts
  • Da Volterra - Pipeline by Indication, 2014
  • Da Volterra - Pipeline by Stage of Development, 2014
  • Da Volterra - Monotherapy Products in Pipeline, 2014
  • Da Volterra - Partnered Products in Pipeline, 2014
  • Da Volterra - Partnered Products/ Combination Treatment Modalities, 2014
  • Da Volterra - Preclinical, 2014
  • Da Volterra - Pipeline by Target, 2014
  • Da Volterra - Pipeline by Route of Administration, 2014
  • Da Volterra - Pipeline by Molecule Type, 2014
  • Da Volterra - Pipeline Products by Mechanism of Action, 2014

List of Figures

  • Da Volterra - Pipeline by Top 10 Indication, 2014
Back to Top